Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx…
Companies covered in this report are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Myriad Genetics, Perkin…
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.…
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new…
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
…
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad…
…
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday…
…
Myriad Genetics (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.…
The Global Hereditary Testing Market Size was valued at USD 6.20 Billion in 2022 and the Worldwide Hereditary Testing Market…
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den…
^Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen…
QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran Partnerschaft umfasst die Entwicklung von im…
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test Myriad can conduct prospective clinical…
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing Research will use Myriad’s high-definition MRD testing platform…
Myriad Genetics (MYGN) announces collaboration with Onsite Womens Health to develop a breast cancer risk assessment program....…
SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test....…
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1...…
Myriad Genetics (MYGN) GeneSight report will contain details on how a patients smoking history may affect their metabolism of certain…
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing…
Strong testing volume improvement across all businesses drives Myriad Genetics (MYGN) Q2 performance....…
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN):Earnings: -$116.1 million in Q2 vs. -$14.1 million…
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response Myriad to support MD Anderson…
SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Spiegelman, Daniel K. - Aufsichtsrat - Tag der Transaktion: 2023-06-02...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test....…
Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation....…